Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Charlottesville, Virginia, that focuses on developing treatments for life-threatening medical conditions. The company's lead product candidate, transcrocetinate sodium, is designed to enhance oxygen delivery to tissues suffering from hypoxia. It is currently undergoing Phase III trials for glioblastoma multiforme and Phase II trials for metastatic brain cancer and acute stroke. Additionally, Diffusion is developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I trials for age-related macular degeneration and is in preclinical development for oncology applications, primarily targeting glioblastoma. The company is also collaborating with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to explore the use of transcrocetinate sodium in patients with acute respiratory distress syndrome related to COVID-19. Founded in 2001, Diffusion Pharmaceuticals is dedicated to addressing significant unmet medical needs through its innovative therapies.